|

IMA203 Product Clinical Trials

1 actively recruiting trial across 1 location

Also known as: anzu-cel, anzutresgene autoleucel

Pipeline

Phase 1/2: 1

Top Sponsors

  • Immatics US, Inc.1

Indications

  • Refractory Cancer1
  • Recurrent Cancer1
  • Solid Tumor, Adult1
  • Cancer1

Stanford, California1 trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Stanford Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.